![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/0/01/Danicopan_structure.svg/640px-Danicopan_structure.svg.png&w=640&q=50)
Danicopan
Medication / From Wikipedia, the free encyclopedia
Danicopan, sold under the brand name Voydeya, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria.[2] It is a complement inhibitor which reversibly binds to factor D to prevent alternative pathway-mediated hemolysis and deposition of complement C3 proteins on red blood cells.[2]
Quick Facts Clinical data, Trade names ...
![]() | |
Clinical data | |
---|---|
Trade names | Voydeya |
Other names | ACH-4471 |
License data | |
Routes of administration | By mouth |
Drug class | Complement factor D inhibitor |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.398.865 ![]() |
Chemical and physical data | |
Formula | C6H3BrFN7O3 |
Molar mass | 320.038 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
Danicopan was approved for medical use in Japan in January 2024,[3] and in the United States in March 2024.[1][4]